Terminated
PHASE2
INTERVENTIONAL
NCT02545127
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Induction and support of lactation in women with preterm delivery and inadequate milk production.
Interventions
Name:
Merotocin
Type:
DRUG
Description:
Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Name:
Placebo
Type:
DRUG
Description:
Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Primary Outcomes
Measure:
Volume of Mother's Own Milk (MoM)
TimeFrame:
Daily days 1 to 14
Description:
Measured by weight in grams converted to volume in milliliters (mL)
Trial Information
NCT ID
NCT02545127
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Ferring Pharmaceuticals
Last Updated
December 15, 2025